2024
Gastrointestinal disease in systemic sclerosis: the neglected organ system?
McMahan Z, Pandolfino J, Perlman H, Del Galdo F, Hinchcliff M. Gastrointestinal disease in systemic sclerosis: the neglected organ system? Current Opinion In Rheumatology 2024, 36: 374-378. PMID: 39193877, PMCID: PMC11588520, DOI: 10.1097/bor.0000000000001052.Peer-Reviewed Original ResearchSystemic sclerosisClinical trial endpointsInflammatory bowel diseaseTrial endpointsAssessment of disease activityRisk stratification methodsGastrointestinal (GIDisease activityRisk stratificationEffective therapyImmune responseBowel diseaseDisease pathogenesisTherapeutic interventionsGastrointestinal diseasesOrgan systemsDiseaseMultidisciplinary teamPathogenesisFunctional studiesGut microbiomeEndpointSclerosis
2023
POS1258 RESULTS FROM A NOMINAL GROUP TECHNIQUE EXERCISE FOR THE CREATION OF A COMBINED RESPONSE INDEX FOR LIMITED CUTANEOUS SYSTEMIC SCLEROSIS: THE CRISTAL PROJECT
Lescoat A, Chen Y, Murphy S, Carroll L, Vann N, Didio P, Iya S, Phanhdone T, Farrington S, Allanore Y, Cella D, Chung L, Clements P, Del Galdo F, Denton C, Distler O, Hinchcliff M, Hughes M, Hummers L, Pauling J, Pope J, Steen V, Varga J, Buch M, Khanna D. POS1258 RESULTS FROM A NOMINAL GROUP TECHNIQUE EXERCISE FOR THE CREATION OF A COMBINED RESPONSE INDEX FOR LIMITED CUTANEOUS SYSTEMIC SCLEROSIS: THE CRISTAL PROJECT. 2023, 971.2-972. DOI: 10.1136/annrheumdis-2023-eular.4633.Peer-Reviewed Original Research
2021
Cellular and Molecular Diversity in Scleroderma
Hinchcliff M, Garcia-Milian R, Di Donato S, Dill K, Bundschuh E, Galdo FD. Cellular and Molecular Diversity in Scleroderma. Seminars In Immunology 2021, 58: 101648. PMID: 35940960, DOI: 10.1016/j.smim.2022.101648.Peer-Reviewed Original ResearchConceptsSystemic sclerosisMedicine approachVariable clinical outcomesPrecision medicine approachPersonalized medicine approachClinical outcomesSame diagnosisDisease heterogeneityDisease riskCare promisesPatient heterogeneityRoutine integrationMolecular heterogeneityMolecular underpinningsSclerosisPatientsSclerodermaHistopathologyMolecular basisArmamentariumFindingsDiagnosisA review and roadmap of the skin, lung and gut microbiota in systemic sclerosis
Teaw S, Hinchcliff M, Cheng M. A review and roadmap of the skin, lung and gut microbiota in systemic sclerosis. Rheumatology 2021, 60: 5498-5508. PMID: 33734316, PMCID: PMC8643452, DOI: 10.1093/rheumatology/keab262.Peer-Reviewed Original Research
2020
Pro-fibrotic Activation of Human Macrophages in Systemic Sclerosis
Bhandari R, Ball M, Martyanov V, Popovich D, Schaafsma E, Han S, Eltanbouly M, Carns M, Arroyo E, Aren K, Hinchcliff M, Whitfield M, Pioli P. Pro-fibrotic Activation of Human Macrophages in Systemic Sclerosis. The Journal Of Immunology 2020, 204: 224.33-224.33. DOI: 10.4049/jimmunol.204.supp.224.33.Peer-Reviewed Original ResearchSystemic sclerosisSSc patientsIL-6IL-6 blockadeHealthy donor monocytesMediator of fibrosisFibrotic activationSSc tissuesInflammatory signatureDonor monocytesPatient macrophagesHealthy donorsTherapeutic targetingBasal conditionsSoluble factorsHuman macrophagesSurface markersMacrophagesPatient's skinElevated levelsGene expression profilesSclerosisPatientsFibrosisImmunophenotypeCirculating classical monocytes share a common transcriptional signature with skin macrophages in Systemic Sclerosis
Makinde H, Dominguez S, Cuda C, Gadhvi G, Aren K, Zeng C, Eickelberg G, Khanna D, Assassi S, Frech T, Winter D, Perlman H, Hinchcliff M. Circulating classical monocytes share a common transcriptional signature with skin macrophages in Systemic Sclerosis. The Journal Of Immunology 2020, 204: 152.12-152.12. DOI: 10.4049/jimmunol.204.supp.152.12.Peer-Reviewed Original ResearchClassical monocytesSSc patientsSystemic sclerosisSkin macrophagesCommon transcriptional signatureEnd-organ fibrosisSystemic sclerosis cohortTranscriptional signatureSites of fibrosisPrecursors of macrophagesUpregulated genesSSc progressionProspective registryControl patientsProinflammatory moleculesSkin biopsiesPatientsMacrophage clustersMacrophagesMonocytesRespective controlsPrecursor populationSclerosisSignificant differencesFibrosis
2019
Towards a new classification of systemic sclerosis
Hinchcliff M, Mahoney JM. Towards a new classification of systemic sclerosis. Nature Reviews Rheumatology 2019, 15: 456-457. PMID: 31217541, DOI: 10.1038/s41584-019-0257-z.Peer-Reviewed Original ResearchComplementary therapies for patients with systemic sclerosis
Showalter K, Hoffmann A, DeCredico N, Thakrar A, Arroyo E, Goldberg I, Hinchcliff M. Complementary therapies for patients with systemic sclerosis. Journal Of Scleroderma And Related Disorders 2019, 4: 187-199. PMID: 35382503, PMCID: PMC8922560, DOI: 10.1177/2397198319833503.Peer-Reviewed Original Research
2018
Diffuse cardiac fibrosis quantification in early systemic sclerosis by magnetic resonance imaging and correlation with skin fibrosis
Lee DC, Hinchcliff ME, Sarnari R, Stark MM, Lee J, Koloms K, Hoffmann A, Carns M, Thakrar A, Aren K, Varga J, Aquino A, Carr JC, Benefield BC, Shah SJ. Diffuse cardiac fibrosis quantification in early systemic sclerosis by magnetic resonance imaging and correlation with skin fibrosis. Journal Of Scleroderma And Related Disorders 2018, 3: 159-169. PMID: 29808171, PMCID: PMC5969530, DOI: 10.1177/2397198318762888.Peer-Reviewed Original ResearchEarly systemic sclerosisT1 mapping parametersSystemic sclerosisSSc patientsDiffuse myocardial fibrosisT1 mapping indicesSkin scoreMyocardial fibrosisSkin fibrosisCardiac structure/functionRodnan skin scoreCardiac magnetic resonance T1 mappingT1 mappingMagnetic resonance imagingMagnetic resonance T1 mappingCardiac involvementCardiovascular evaluationConsecutive patientsClinical studiesPatientsResonance imagingFibrosisFibrosis quantificationCine imagingSclerosis
2017
Reliability and Validity of the Tender and Swollen Joint Counts and the Modified Rodnan Skin Score in Early Diffuse Cutaneous Systemic Sclerosis: Analysis from the Prospective Registry of Early Systemic Sclerosis Cohort.
Gordon JK, Girish G, Berrocal VJ, Zhang M, Hatzis C, Assassi S, Bernstein EJ, Domsic RT, Hant FN, Hinchcliff M, Schiopu E, Steen VD, Frech TM, Khanna D. Reliability and Validity of the Tender and Swollen Joint Counts and the Modified Rodnan Skin Score in Early Diffuse Cutaneous Systemic Sclerosis: Analysis from the Prospective Registry of Early Systemic Sclerosis Cohort. The Journal Of Rheumatology 2017, 44: 791-794. PMID: 28298560, PMCID: PMC5457319, DOI: 10.3899/jrheum.160654.Peer-Reviewed Original ResearchConceptsDiffuse cutaneous systemic sclerosisSwollen joint countCutaneous systemic sclerosisRodnan skin scoreMusculoskeletal ultrasoundJoint countSkin scoreSystemic sclerosisEarly diffuse cutaneous systemic sclerosisModified Rodnan skin scoreSystemic sclerosis cohortProspective registryTJCExcellent interMRSSSJCSclerosisContent validityScoresCountRheumatologistsPatientsRegistryCohortAbnormalities
2016
Comment on “Esophageal dilatation and interstitial lung disease in systemic sclerosis: A cross-sectional study”
Hoffmann A, Lee J, Ma M, Agrawal R, Chang RW, Richardson C, Hinchcliff M, Showalter K. Comment on “Esophageal dilatation and interstitial lung disease in systemic sclerosis: A cross-sectional study”. Seminars In Arthritis And Rheumatism 2016, 46: e11-e12. PMID: 27312382, PMCID: PMC6701947, DOI: 10.1016/j.semarthrit.2016.04.006.Peer-Reviewed Original Research
2015
Cardiac metabolomics and autopsy in a patient with early diffuse systemic sclerosis presenting with dyspnea: a case report
Frech TM, Revelo MP, Ryan JJ, Shah AA, Gordon J, Domsic R, Hant F, Assassi S, Shanmugam VK, Hinchcliff M, Steen V, Khanna D, Bernstein EJ, Cox J, Luem N, Drakos S. Cardiac metabolomics and autopsy in a patient with early diffuse systemic sclerosis presenting with dyspnea: a case report. Journal Of Medical Case Reports 2015, 9: 136. PMID: 26055398, PMCID: PMC4469401, DOI: 10.1186/s13256-015-0587-7.Peer-Reviewed Original ResearchConceptsDiffuse systemic sclerosisSystemic sclerosisCardiac deathCase reportTissue metabolomicsEarly diffuse systemic sclerosisCardiac magnetic resonance imagingRight heart catheterizationPulmonary function testsCaucasian female patientSystemic sclerosis pathogenesisMagnetic resonance imagingRenal crisisHeart catheterizationCase presentationADigital ulcerationFemale patientsFunction testsSkin thickeningRare diseaseDisease pathogenesisHigh mortalityResonance imagingDyspneaSclerosis
2014
Advances in the Evaluation and Management of Esophageal Disease of Systemic Sclerosis
Carlson DA, Hinchcliff M, Pandolfino JE. Advances in the Evaluation and Management of Esophageal Disease of Systemic Sclerosis. Current Rheumatology Reports 2014, 17: 475. PMID: 25475597, PMCID: PMC4343525, DOI: 10.1007/s11926-014-0475-y.Peer-Reviewed Original ResearchConceptsSystemic sclerosisEsophageal diseaseAbnormal esophageal acid exposureGastroesophageal reflux disease treatmentSymptoms of heartburnEsophageal acid exposureProton pump inhibitorsEsophageal dysmotilityPump inhibitorsGERD managementObjective findingsReflux monitoringClinical characterizationEndoscopic ultrasoundAcid exposureImpedance planimetryDiagnostic testingDiseaseDisease treatmentSclerosisPatientsTreatmentDysmotilityHeartburnDysphagiaSystemic sclerosis: beyond limited and diffuse subsets?
Varga J, Hinchcliff M. Systemic sclerosis: beyond limited and diffuse subsets? Nature Reviews Rheumatology 2014, 10: 200-202. PMID: 24535544, PMCID: PMC5438483, DOI: 10.1038/nrrheum.2014.22.Peer-Reviewed Original Research
2013
Treatment of early diffuse systemic sclerosis skin disease.
Frech TM, Shanmugam VK, Shah AA, Assassi S, Gordon JK, Hant FN, Hinchcliff ME, Steen V, Khanna D, Kayser C, Domsic RT. Treatment of early diffuse systemic sclerosis skin disease. Clinical And Experimental Rheumatology 2013, 31: 166-71. PMID: 23910619, PMCID: PMC3889109.Peer-Reviewed Original ResearchConceptsSSc skin diseaseSystemic sclerosisSkin diseasesEarly diffuse cutaneous systemic sclerosisDiffuse cutaneous systemic sclerosisEarly diffuse SScEarly systemic sclerosisCutaneous systemic sclerosisDiffuse systemic sclerosisIncident cohort studyIntravenous immunoglobulinProspective registryCohort studyInter-institutional variabilityClinical courseHigh morbidityDiffuse SScEffective treatmentNovel biomarkersDisease pathogenesisSclerosisDiseaseTreatmentRigorous studiesMycophenolateAssessment of diffuse myocardial fibrosis in systemic sclerosis by cardiac magnetic resonance imaging
Lee D, Sarnari R, Benefield B, Aquino A, Carr J, Varga J, Hinchcliff M, Wu E, Shah S. Assessment of diffuse myocardial fibrosis in systemic sclerosis by cardiac magnetic resonance imaging. Journal Of Cardiovascular Magnetic Resonance 2013, 15: e121. PMCID: PMC3559286, DOI: 10.1186/1532-429x-15-s1-e121.Peer-Reviewed Original Research
2012
The Pulmonary Fibrosis-Associated MUC5B Promoter Polymorphism Does Not Influence the Development of Interstitial Pneumonia in Systemic Sclerosis
Peljto AL, Steele MP, Fingerlin TE, Hinchcliff ME, Murphy E, Podlusky S, Carns M, Schwarz M, Varga J, Schwartz DA. The Pulmonary Fibrosis-Associated MUC5B Promoter Polymorphism Does Not Influence the Development of Interstitial Pneumonia in Systemic Sclerosis. CHEST Journal 2012, 142: 1584-1588. PMID: 22576636, PMCID: PMC3515031, DOI: 10.1378/chest.12-0110.Peer-Reviewed Original ResearchConceptsInterstitial pneumoniaSystemic sclerosisPromoter polymorphismDistinct genetic risk factorsMUC5B Promoter PolymorphismUnaffected control subjectsGenetic risk factorsReticular infiltratesLung involvementControl subjectsRisk factorsIP diagnosisSporadic formsSecondary analysisFVCPneumoniaSclerosisCommon variantsConservative definitionPhenotypic heterogeneitySubjectsMinor allele frequencyPolymorphismAllele frequenciesAssociation
2011
Identification of Novel Genetic Markers Associated with Clinical Phenotypes of Systemic Sclerosis through a Genome-Wide Association Strategy
Gorlova O, Martin JE, Rueda B, Koeleman BP, Ying J, Teruel M, Diaz-Gallo LM, Broen JC, Vonk MC, Simeon CP, Alizadeh BZ, Coenen MJ, Voskuyl AE, Schuerwegh AJ, van Riel PL, Vanthuyne M, van 't Slot R, Italiaander A, Ophoff RA, Hunzelmann N, Fonollosa V, Ortego-Centeno N, González-Gay MA, García-Hernández FJ, González-Escribano MF, Airo P, van Laar J, Worthington J, Hesselstrand R, Smith V, de Keyser F, Houssiau F, Chee MM, Madhok R, Shiels PG, Westhovens R, Kreuter A, de Baere E, Witte T, Padyukov L, Nordin A, Scorza R, Lunardi C, Lie BA, Hoffmann-Vold AM, Palm Ø, García de la Peña P, Carreira P, , Varga J, Hinchcliff M, Lee AT, Gourh P, Amos CI, Wigley FM, Hummers LK, Hummers J, Nelson J, Riemekasten G, Herrick A, Beretta L, Fonseca C, Denton C, Gregersen P, Agarwal S, Assassi S, Tan F, Arnett F, Radstake T, Mayes M, Martin J. Identification of Novel Genetic Markers Associated with Clinical Phenotypes of Systemic Sclerosis through a Genome-Wide Association Strategy. PLOS Genetics 2011, 7: e1002178. PMID: 21779181, PMCID: PMC3136437, DOI: 10.1371/journal.pgen.1002178.Peer-Reviewed Original ResearchConceptsSystemic sclerosisSSc patientsHLA regionDiffuse cutaneous involvementHLA-DQB1 lociNon-HLA genesCutaneous involvementHealthy controlsIndependent associationHLA-DQB1Antibody subgroupsIndependent cohortGenome-wide association studiesClinical phenotypeGenetic componentIRF8 geneLcSScSclerosisPatientsSubgroupsCohortSuggestive associationAssociationNovel genetic markersGWAS level
2007
Novel paradigm for treating vasculopathy in systemic sclerosis: Vascular progenitor cells and statins
Hinchcliff M, Varga J. Novel paradigm for treating vasculopathy in systemic sclerosis: Vascular progenitor cells and statins. Current Rheumatology Reports 2007, 9: 1-3. PMID: 17437659, DOI: 10.1007/s11926-007-0014-1.Peer-Reviewed Original ResearchObliterative vasculopathy in systemic sclerosis: endothelial precursor cells as novel targets for therapy
Hinchcliff M, Varga J. Obliterative vasculopathy in systemic sclerosis: endothelial precursor cells as novel targets for therapy. Expert Review Of Clinical Immunology 2007, 3: 11-15. PMID: 20476946, DOI: 10.1586/1744666x.3.1.11.Peer-Reviewed Original ResearchSystemic sclerosisObliterative vasculopathyOpen-label clinical trialEfficacy of statinsChronic cardiovascular diseasePrecursor cellsSerious clinical manifestationsEndothelial precursor cellsChronic vasculopathyVascular obliterationClinical manifestationsVascular damageVascular precursor cellsClinical trialsTherapeutic roleCardiovascular diseaseEffective treatmentImpaired productionVasculopathySclerosisNovel targetStatinsDefective vasculogenesisAtorvastatinEndothelial precursors